An Update on the Use of Sodium Glucose Cotransporter Type 2 Inhibitors in Patients Receiving Kidney Transplants

Burlacu Snyder^*
*Correspondence: Burlacu Snyder, Department of Transplant Surgery, North Bristol University, Bristol, UK, Email:

Introduction

Sodium Glucose Cotransporter Type 2 (SGLT2) inhibitors have emerged as a significant advancement in the management of type 2 Diabetes Mellitus (T2DM) and are now gaining attention for their potential benefits beyond glycemic control, particularly in the context of kidney health. Given the high prevalence of diabetes among kidney transplant recipients, understanding the implications of SGLT2 inhibitors in this population is crucial. This article provides an updated overview of the use of SGLT2 inhibitors in patients receiving kidney transplants, exploring their effects on glycemic control, renal function, cardiovascular outcomes, and potential adverse effects. SGLT2 inhibitors work by blocking the reabsorption of glucose in the proximal convoluted tubule of the nephron, leading to increased glucose excretion in the urine. This mechanism results in a reduction in blood glucose levels, weight loss, and a mild diuretic effect. The benefits of SGLT2 inhibitors extend beyond glycemic control; they also confer renal protective effects, which are particularly relevant in the context of kidney transplantation. Diabetes is a common comorbidity in kidney transplant recipients, with studies indicating that approximately 30-50% of patients develop New-Onset Diabetes After Transplantation (NODAT). The risk factors for NODAT include pre-existing diabetes, obesity, and the use of immunosuppressive therapies such as corticosteroids. Given the detrimental impact of diabetes on transplant outcomes, effective management is essential. SGLT2 inhibitors are effective in achieving glycemic control in patients with T2DM. In the post-transplant setting, where maintaining stable glucose levels is critical, these agents can provide an alternative to traditional antidiabetic medications. Their unique mechanism of action, which does not involve insulin secretion, reduces the risk of hypoglycemia, making them suitable for a diverse patient population [1].

Description

The renal protective effects of SGLT2 inhibitors have been demonstrated in various studies involving patients with Chronic Kidney Disease (CKD) and those at risk for renal impairment. SGLT2 inhibitors lower intraglomerular pressure by reducing the volume of fluid entering the nephron, mitigating hyperfiltration injury, which is particularly relevant post-transplant. These agents have anti-inflammatory properties and may reduce renal interstitial fibrosis, contributing to improved graft function over time. Early studies suggest that SGLT2 inhibitors may help stabilize renal function in transplant recipients, potentially translating into better long-term outcomes. Patients with diabetes, particularly those with CKD or post-transplant, are at heightened risk for cardiovascular events. SGLT2 inhibitors have demonstrated cardiovascular benefits, including reductions in heart failure hospitalizations and cardiovascular mortality. In kidney transplant patients, these cardiovascular effects can be particularly important, as they are often older and have multiple comorbidities [2].

Recent clinical trials and observational studies have begun to explore the safety and efficacy of SGLT2 inhibitors in kidney transplant recipients. Early studies indicate that SGLT2 inhibitors are generally safe and welltolerated in kidney transplant recipients. They do not appear to adversely affect immunosuppressive drug levels, which is a crucial consideration in this population. However, monitoring for potential adverse effects, such as Urinary Tract Infections (UTIs) and Diabetic Ketoacidosis (DKA), remains essential. Guidelines from various nephrology and transplant organizations are evolving to incorporate SGLT2 inhibitors into the management of diabetes in kidney transplant recipients. While the specific recommendations may vary, there is a growing consensus on their potential utility, particularly for patients with concurrent T2DM and high cardiovascular risk. Ongoing clinical trials are examining the long-term effects of SGLT2 inhibitors in kidney transplant patients, including their impact on graft survival and the prevention of NODAT. Preliminary results suggest favorable outcomes, but further research is necessary to establish definitive recommendations [3]. Congenital adrenal hyperplasia is an inherited disorder caused by enzyme deficiencies in cortisol biosynthesis, leading to impaired cortisol production and excess adrenal androgen synthesis. In severe cases, salt-wasting adrenal crisis may occur in neonates. Treatment involves lifelong glucocorticoid and mineralocorticoid replacement therapy to maintain adrenal hormone balance and prevent adrenal crises. Adrenal insufficiency results from inadequate adrenal hormone production, commonly due to autoimmune destruction (primary adrenal insufficiency or Addison's disease) or pituitary dysfunction (secondary adrenal insufficiency). Symptoms include fatigue, weight loss, hypotension, and electrolyte abnormalities. Treatment consists of lifelong glucocorticoid and mineralocorticoid replacement therapy to manage symptoms and prevent adrenal crises [4].

The mechanism of action of SGLT2 inhibitors increases urinary glucose excretion, which can predispose patients to UTIs. In the transplant population, where infections are a significant concern due to immunosuppression, this risk warrants careful consideration and monitoring. Although rare, there have been reports of DKA in patients taking SGLT2 inhibitors. This risk may be heightened in patients undergoing stress (e.g., surgery, infections) or those with inadequate insulin coverage. Education on recognizing the signs and symptoms of DKA is essential for patients and healthcare providers. The diuretic effect of SGLT2 inhibitors can lead to volume depletion, particularly in patients already at risk for hypotension due to concurrent medications. Careful monitoring of blood pressure and renal function is essential, especially after initiation of therapy [5].

Conclusion

SGLT2 inhibitors represent a promising therapeutic option for managing diabetes in kidney transplant recipients. Their potential benefits, including improved glycemic control, renal protection, and cardiovascular benefits, position them as a valuable addition to the post-transplant management regimen. However, careful patient selection and monitoring for adverse effects are essential to optimize outcomes. As more data become available, guidelines will continue to evolve, providing clearer recommendations for the use of SGLT2 inhibitors in this unique patient population. Future research will be critical in confirming the long-term benefits and safety profiles of these agents, ultimately contributing to improved care for kidney transplant recipients.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Badrouchi, Samarra, Mohamed Mongi Bacha, Hafedh Hedri and Taieb Ben Abdallah, et al. "Toward generalizing the use of artificial intelligence in nephrology and kidney transplantation." J Nephrol 36 (2023): 1087-1100.

Google Scholar, Crossref, Indexed at

2. Niel, Olivier and Paul Bastard. "Artificial intelligence in nephrology: Core concepts, clinical applications, and perspectives." Am J Kidney Dis 74 (2019): 803-810.

Google Scholar, Crossref, Indexed at

3. Hueso, Miguel, Alfredo Vellido, Nuria Montero and Carlo Barbieri, et al. "Artificial intelligence for the artificial kidney: pointers to the future of a personalized hemodialysis therapy." Kidney Dis 4 (2018): 1-9.

Google Scholar, Crossref, Indexed at

4. Lai, Gu-Shun, Jian-Ri Li, Shian-Shiang Wang and Chuan-Shu Chen, et al. "Influence of Surgical Complications on Outcomes in Kidney Transplantation Patients." in vivo 37 (2023): 2796-2802.

Google Scholar, Crossref, Indexed at

5. Ali, Hatem, Mahmoud Mohamed, Miklos Z. Molnar and Tibor Fülöp, et al. "Deceased-donor kidney transplant outcome prediction using artificial intelligence to aid decision-making in kidney allocation." ASAIO J (2024): 10-1097.

Google Scholar, Crossref, Indexed at